OLIPASS
OliPass Corporation is committed to revolutionize our views of life sciences and bring us great quality of life.
OLIPASS
Industry:
Biotechnology Life Science
Founded:
2006-01-01
Address:
Suwon, Ch'ungch'ong-namdo, South Korea
Country:
South Korea
Website Url:
http://www.olipass.com
Total Employee:
51+
Status:
Active
Total Funding:
20 B KRW
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Google Universal Analytics Apache
Similar Organizations
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Current Employees Featured
Founder
Investors List
Geon Investment
Geon Investment investment in Venture Round - Olipass
Official Site Inspections
http://www.olipass.com
- Host name: 172.67.210.125
- IP address: 172.67.210.125
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Olipass"
Olipass - Crunchbase Company Profile & Funding
OliPass is always collaborating to develop new ways to give a happy and healthy existence for everyone on the planet. OliPass Corporation is dedicated to changing people's perceptions of โฆSee details»
OliPass
OliPass is dedicated to providing safe and feasible options for healthy aging. History. 2020โs. 2022 09 Drug development R&D collaboration with Vanda Pharmaceuticals Inc. 09 Presented โฆSee details»
OliPass
OliPass PNA is highly permeable to skin, so it is also suitable to be developed for treating various skin diseases such as atopic dermatitis, psoriasis and the like. Also due to its excellent skin โฆSee details»
Shin Chung๋ - CEO - OliPass Corporation - LinkedIn
Nov 19, 2018 Founder & CEO, OliPass Corporation · I have been in the pharmaceutical industry and involved in drug discovery and development for more than 30 years. My professional โฆSee details»
OliPass
OliPass PNA(OPNA) ํ์ด์ง ๋ฐ๋ก๊ฐ๊ธฐ OliPass Peptide Nucleic Acid (OliPass PNA) is derived from PNA by rationally introducing cationic lipid moiety onto nucleobase. By covalently attaching โฆSee details»
OliPass - VentureRadar
Since 2006, OliPass has been committed to revolutionizing the life sciences and improving the quality of life. Our research is focused on developing a new generation of therapeutics using โฆSee details»
OliPass Corporation Overview | SignalHire Company Profile
Organization Website: olipass.com : Phone Number +82-2-6488-2239: OliPass Corporation industries ... OliPass Corporation headquarters is in ์์ธ์, ๊ฐ๋๊ตฌ ์ฒํธ๋๋ก 1077 โฆSee details»
OLIPASS Corporation: Shareholders, Shareholding Structure
OliPass Corporation is a Korea-based company principally engaged in the research and development of bio medicine. The Company principally manufactures and sells nonopioid โฆSee details»
์ฌ๋ฆฌํจ์ค ์์์์ด Real Beauty
Jan 11, 2022 company : (์ฃผ)์ฌ๋ฆฌํจ์ค ์์์์ด ceo : ์ ์ business licence : [299-87-00218] e-commerce permit ์ 2017-์ฉ์ธ๊ธฐํฅ-0807ํธ [์ฌ์ ์์ ๋ณดํ์ธ] phone : 02-6488-2373 fax : 02 โฆSee details»
Home | Citeline
Clinical Citeline Clinical provides comprehensive real-time R&D intelligence to the life sciences industry, featuring an unmatched data collection of global clinical trials, vetted investigators, trial โฆSee details»
Olipass Corporation (244460) Income Statement - Investing.com AU
The Income Statement (earnings report) for Olipass Corporation. Find the company's financial performance, revenue, and more.See details»
OliPass
OliPass PNA(OPNA)๋ PNA์ ์ผ๋ถ ํต์ฐ ์ผ๊ธฐ์ "์์ด์จ์ฑ ์ง์ง๊ธฐ"๋ฅผ ํํ์ ์ผ๋ก ๋์ ํ "PNA ์ ๋์ฒด"์ ๋๋ค. ์ด๋ฌํ "OPNA"๋ ์ธํฌํฌ๊ณผ์ฑ์ด ๋ฐ์ด๋ ํต๋ด ์ฝ๋ฌผ ๋ถํฌ๊ฐ ์ฉ์ดํ์ฌ Exon โฆSee details»
Vanda ๅ OliPass ่พพๆๆ็ฅๅไฝไผไผดๅ ณ็ณป๏ผๅ ฑๅๅผๅๅไนๅฏกๆ ธ่ท้ ธ โฆ
ๆฌข่ฟๅ ณๆณจๅฏ่ฑ่ฑ่ฏ้ป. 2022ๅนด9ๆ29ๆฅ๏ผVanda Pharmaceuticals๏ผ็ฎ็งฐโVandaโ๏ผๅOliPassๅ ฌๅธๅ ฑๅๅฎฃๅธ๏ผไบ่ ๅทฒ่พพๆไธ้กน็ ๅๅไฝๅ่ฎฎ๏ผๅ ฑๅๅผๅๅบไบOliPassไธๆไฟฎ้ฅฐ ่ฝๆ ธ้ ธ ็ๅไนๅฏกๆ ธ่ท โฆSee details»
์ฌ๋ฆฌํจ์ค(OliPass) ๊ธฐ์ ๋ฐ ์ฐ์ ๋ถ์! : ๋ค์ด๋ฒ ๋ธ๋ก๊ทธ
์ฌ๋ฆฌํจ์ค๋ 2006๋ 11์์ ์ค๋ฆฝ๋์ด ์ธํฌํฌ๊ณผ์ฑ์ด ์ฐ์ํ ์ฌ๋ฆฌ๊ณ ๋ดํด๋ ์คํฐ๋๋ฅผ ๋ง๋๋ ๊ณ ์ ์ ํ๋ซํผ ๊ธฐ์ ์ ๊ธฐ๋ฐ์ผ๋ก rna ์น๋ฃ์ ์ ์ฝ๊ฐ๋ฐ์ ์ฃผ๋ ฅ์ฌ์ ์ผ๋ก ์์ ํ๊ณ ์์ต๋๋ค. ํ์ฌ๋ ํ์ฌ โฆSee details»
OliPass Discloses Painful but Hilarious Clinical Findings from a โฆ
SEOUL, South Korea, Nov. 13, 2023 /PRNewswire/ -- OliPass Corporation, an RNA therapeutics platform company, disclosed uncanny clinical findings from a multi-center Phase 2a trial with โฆSee details»
Nav1.7 Selective Inhibitor OLP-1002 Shows Strong Efficacy
Mar 16, 2023 OliPass Corporation, an RNA therapeutics platform company, disclosed that OLP-1002, a selective inhibitor of Nav1.7 sodium ion channel, showed strong analgesic efficacy โฆSee details»
OliPass
However as the mechanism of action of OliPass PNA has been elucidated as exon skipping, we plan to invest our R&D to build a portfolio of pipelines focusing on clinical development. In โฆSee details»
OLP-1002 / Olipass - LARVOL DELTA - delta.larvol.com
Olipass acquires patent for non-narcotic painkiller 'OLP-1002' [Google translation] (HIT News) - "Olipass...has acquired a Chinese patent for 'OLP-1002 (development code name)', a non โฆSee details»
OliPass
์์ธ๋ฌ "OliPass PNA"๋ ์ ์ ์ ๊ฒฐํฉ๋ ฅ์ด ๋งค์ฐ ๊ฐํ ํน์ฑ๋ ๋ณด์ ํ๊ณ ์์ต๋๋ค. "OliPass PNA"๋ ๋ณ๋์ ์ ํ ์์ด ์ธํฌ ๋ฐ ๋๋ฌผ์์ ์น๋ฃ ํจ๋ฅ์ด ์ป์ด์ง๊ธฐ ๋๋ฌธ์ "์ธ๊ณต์ ์ ์ ์น๋ฃ์ "๊ฐ๋ฐ์ ๋งค์ฐ โฆSee details»
OLP-1002 (OLP-1002) - ่ฏ็ฉ้ถ็น๏ผNav1.7_ๅจ็ ้ๅบ็๏ผ้ชจๅ ณ่ โฆ
OLP-1002: ไธ็งSCN9Aๅบๅ ๆๅถๅ่ฏ็ฉ๏ผ็ฑOliPass Corp. (OliPass Corp.)ๅ ฌๅธๆๆฉ่ฟ่ก็ ๅ๏ผ็ฎๅๅ จ็ๆ้ซ็ ๅ็ถๆไธบไธดๅบ2ๆ๏ผไฝ็จๆบๅถ: SCN9Aๅบๅ ๆๅถๅ(IXๅ้ ้้่็ฝฮฑไบๅบๅบๅ ๆ โฆSee details»